EU and US could reach trade deal this weekend - Reuters
INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY), a pharmaceutical giant with a market capitalization of $690 billion, announced Monday that its board of directors has declared a quarterly dividend of $1.50 per share on outstanding common stock for the third quarter of 2025. The company has maintained dividend payments for 55 consecutive years, according to InvestingPro data.
The dividend will be payable on September 10, 2025, to shareholders of record as of August 15, 2025, according to a company press release.
Eli Lilly, a global pharmaceutical company founded nearly 150 years ago, develops medicines across multiple therapeutic areas including diabetes, obesity, Alzheimer’s disease, immunology, and oncology.
The quarterly dividend announcement comes as part of the company’s regular financial operations. Eli Lilly currently serves tens of millions of patients worldwide with its pharmaceutical products.
The company noted in its statement that forward-looking statements about expected dividend payments are subject to various risks and uncertainties that could cause actual results to differ from expectations, as detailed in Lilly’s SEC filings.
In other recent news, Eli Lilly’s developments have captured significant attention in the pharmaceutical sector. The European Medicines Agency has initiated a re-examination of Eli Lilly’s Alzheimer’s drug, Kisunla, after initially recommending against its approval. This re-evaluation could potentially lead to the drug’s acceptance in the European market. Meanwhile, the American College of Cardiology has recommended Eli Lilly’s weight-loss drug, Zepbound, as a primary treatment for obese patients to prevent heart disease, marking a shift from previous guidelines that favored lifestyle changes.
In addition, Eli Lilly’s metabolic portfolio received positive attention at the American Diabetes Association event. BMO Capital reiterated its Outperform rating, highlighting the company’s advancements in metabolic treatments, including its oral GLP-1 asset, naperiglipron. Truist Securities maintained a Buy rating on Eli Lilly, noting a favorable risk/benefit profile for its oral diabetes drug, orforglipron, despite some safety concerns. Cantor Fitzgerald also reiterated its Overweight rating, emphasizing the potential of Eli Lilly’s weight-loss drug pipeline, particularly the amylin receptor agonist, eloralintide. These recent developments underscore Eli Lilly’s ongoing efforts and strategic positioning in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.